---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Diagnosis"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Diagnosis. Topics: Whipple triad: diagnostic hallmark of a hypoglycemic disorder; Endocrine Society guideline: evaluation of adults with hypoglycemia; Insulinoma: biochemical diagnostic criteria; Insulinoma: corrected insulin, C-peptide, and proinsulin thresholds; 12 further topics. 16 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/diagnosis"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Whipple triad: diagnostic hallmark of a hypoglycemic disorder

> “The Whipple triad, named after the American surgeon Allen O. Whipple (1881-1963), is the diagnostic hallmark establishing the existence of a hypoglycemic disorder and has the following 3 features: (1) symptoms, signs, or both consistent with hypoglycemia; (2) low plasma glucose measured at the time of the symptoms and signs; and (3) relief of symptoms and signs when the glucose is raised to a normal level”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.5-2"></a>

### Endocrine Society guideline: evaluation of adults with hypoglycemia

> “We recommend evaluation and management of hypoglycemia only in patients in whom Whipple's triad”
> “In patients suspected of having endogenous hyperinsulinism, measure plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and circulating oral hypoglycemic agents during an episode of hypoglycemia and measure insulin antibodies.”

Source: [Cryer et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19088155/)

<a id="topic-2.2.1.5-3"></a>

### Insulinoma: biochemical diagnostic criteria

> “Thus, in patients with insulinoma, plasma insulin, C-peptide, and proinsulin concentrations are inappropriately high in the setting of low fasting plasma glucose concentrations”
> “According to the most recent clinical practice guidelines, critical diagnostic findings are present when the confirmed fasting plasma glucose concentrations are preferably below 45 mg/dL (2.5 mmol/L) or below 55 mg/dL (3.0 mmol/L)”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.5-4"></a>

### Insulinoma: corrected insulin, C-peptide, and proinsulin thresholds

> “plasma insulin concentrations of at least 3 μU/mL (18 pmol/L), plasma C-peptide concentrations of at least 0.6 ng/mL (0.2 nmol/L), and plasma proinsulin concentrations of at least 5.0 pmol/L”

Source: [Journal of Clinical Endocrinology and Metabolism insulinoma correction (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13271780/)

> “The sensitivity and specificity of the established diagnostic criteria using insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and glucose response to iv glucagon were greater than 90% and greater than 70%, respectively.”

Source: [Placzkowski et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19141587/)

<a id="topic-2.2.1.5-5"></a>

### Insulinoma: supervised prolonged fasting test

> “If hypoglycemia does not occur spontaneously, a 72-hour prolonged fasting test should be performed and blood should be drawn for measurements of insulin, and pro-insulin, or C-peptide measurements if hypoglycemia occurs.”
> “Some authors have advocated shorter fasting tests”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “We identified 127 patients with insulinoma.”
> “The fast was terminated due to hypoglycemia in 44 patients (42.5%) by 12 h, 85 patients (66.9%) by 24 h, and 120 (94.5%) by 48 h.”
> “Thus, the 48-h fast should replace the 72-h fast in textbooks and hospital protocols as the new diagnostic standard.”

Source: [Hirshberg et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10999812/)

> “Sixty-five patients underwent a fasting test, aiming at a 24, 36, or 72-hour fasting time.”
> “were met in 92% of the tests, after a median fasting time of 14 (0, 36) hours.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

<a id="topic-2.2.1.5-6"></a>

### Insulinoma: beta-hydroxybutyrate stopping criterion in the 72-hour fast

> “After the update, 50% (N = 15) ended for BHB >2.7 mmol/L, with an average fast duration of 49.7 hours (median 53 hours, IQR [39.1, 71.8], P = .03).”
> “All insulinoma cases (N = 7) developed hypoglycemia within 43 hours with BHB ≤1.2 mmol/L; no cases were missed.”

Source: [Lundholm et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40288609/)

<a id="topic-2.2.1.5-7"></a>

### Insulinoma: localization imaging strategy

> “Localization of the insulinoma and exclusion or confirmation of metastatic disease by CT is still the preferred initial localization modality followed by EUS or magnetic resonance imaging (MRI) for indolent, localized insulinomas”
> “Glucagon-like peptide 1 receptor (GLP-1R) PET/CT or PET/MRI is a highly sensitive localization technique for seemingly occult, indolent, localized insulinomas and has become increasingly popular.”
> “Preoperative localization of nonmetastatic insulinomas is important and sometimes difficult, because approximately 30% of insulinomas are less than 10 mm in diameter.”
> “However, as opposed to localized indolent insulinomas, aggressive malignant insulinomas often lack the expression of the GLP-1R.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.5-8"></a>

### Insulinoma: sensitivity and specificity of localization modalities across published studies

| Modality | Sensitivity | Specificity |
| --- | --- | --- |
| CT | “54%” | “75%” |
| MRI | “54%” | “65%” |
| EUS | “81%” | “90%” |
| ASVS | “93%” | “86%” |
| SSTR SPECT | “53%” | “50%” |
| SSTR PET | “39%” | “14%” |
| GLP-1R SPECT | “83%” | “40%” |
| GLP-1R PET | “87%” | “94%” |

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.5-9"></a>

### Insulinoma: GLP-1 receptor PET/CT in a prospective multicenter comparison

> “Sixty-nine adults with biochemically proven adult endogenous hyperinsulinemic hypoglycemia underwent exendin PET/CT and current routine imaging.”
> “Based on clinical readings, the accuracy of exendin PET/CT (94.4%; 95% CI, 84.6%–98.8%) was greater than that of DOTA-SSA PET/CT (64.8%; 95% CI, 50.6%–77.3%), contrast-enhanced CT/contrast-enhanced diffusion-weighted imaging-MRI (83.3%; 95% CI, 70.7%–92.1%), and endoscopic ultrasound (82.8%; 95% CI, 64.1%–94.1%).”
> “In 13% of patients, a correct diagnosis was only reached after exendin PET/CT.”

Source: [Boss et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11619583/)

<a id="topic-2.2.1.5-10"></a>

### Insulinoma: GLP-1 receptor SPECT/CT in a prospective multicenter study

> “For 23 assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [95% CI 74-100]) than did CT/MRI (47% [27-68]; p=0.011).”
> “Seven patients (23%) were referred to surgery on the basis of (111)In-DTPA-exendin-4 imaging alone.”

Source: [Christ et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24622317/)

<a id="topic-2.2.1.5-11"></a>

### Insulinoma: preoperative localization over time in cohort studies

> “The overall imaging sensitivity improved from 39% in the 1980s to 98% in the 2000s”
> “The tumour was localized preoperatively in 59 (75%) of the patients.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

> “Although the rates of localization by noninvasive techniques remained static at approximately 75%, the addition of invasive modalities has resulted in successful preoperative localization in all patients in the past 10 yr.”

Source: [Placzkowski et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19141587/)

<a id="topic-2.2.1.5-12"></a>

### Insulinoma: diagnostic delay and prior misdiagnosis

> “The median diagnostic delay was 13 months and did not change over the study period.”
> “Thirty-one of 79 patients were first examined for their symptoms by specialities other than endocrinology, most often by neurology, neurosurgery, or cardiology.”
> “The episodic symptoms were often interpreted as cerebrovascular disorders, epilepsy, or psychiatric disorders.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

> “The interval from the onset of symptoms to diagnosis ranged from 1 month to 30 years (median 24 months).”
> “Prior diagnoses included neurologic disorders (64%), especially seizure disorders (39%); 7 (12%) patients were treated with antiseizure medications.”

Source: [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)

<a id="topic-2.2.1.5-13"></a>

### Malignant insulinoma: biochemical and tumor-size features at diagnosis

> “Patients with malignant insulinoma presented with higher levels of insulin, proinsulin, and c-peptide.”
> “Malignant lesions were larger: 4.2 ± 3.2 vs 1.8 ± 0.8 cm in benign lesions, p < 0.01.”

Source: [Sada et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32873371/)

<a id="topic-2.2.1.5-14"></a>

### NICTH: biochemical pattern and IGF-2 to IGF-1 ratio

> “In a hypoglycemic patient with low insulin and C-peptide, a low β-hydroxybutyrate level suggests an agent mimicking insulin and is therefore an indication to measure IGF-I and IGF-II”
> “The typical pattern for NICTH on the above laboratory studies includes low glucose (serum glucose < 55 mg/dL) with simultaneous low insulin/proinsulin/C-peptide/β-hydroxybutyrate levels, and the absence of positive results on an oral hypoglycemic agent screen.”
> “This ratio may be an important screening tool for NICTH in cases of hypoglycemia”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

> “Typically, the elevated IGF-2 levels are associated with suppressed plasma levels of insulin, IGF-1, and GH.”

Source: [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)

> “A ratio of IGF‐2 and IGF‐1 in a healthy individual is 3:1. A molar ratio larger than 10 in recurrent hypoglycaemia supports NICTH.”
> “an 88% positivity rate for IGF2:IGF1 ratio>10”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.1.5-15"></a>

### NICTH: hypoinsulinemia and tumor size in a Japanese case series

> “Basal immunoreactive insulin (IRI) levels were less than 3 microU/dl in 79% of the patients.”
> “The diameters of the tumors were more than 10 cm in 70% of the patients.”
> “These data suggested that hypoinsulinemic hypoglycemia associated with the presence of a large tumor supports the diagnosis of IGF-II producing NICTH.”

Source: [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)

<a id="topic-2.2.1.5-16"></a>

### NICTH: test availability and tumor imaging

> “To our knowledge, there is no commercially available assay for big IGF-II, and measurement of high molecular weight precursor forms of IGF-II must be done in a research laboratory setting at this time.”
> “If laboratory results suggest NICTH (eg, high IGF-II:IGF-I ratio and absence of evidence for hyperinsulinemia), a reasonable next step is cross-sectional imaging of the chest, abdomen, and pelvis to identify a tumor, given that the vast majority of reported cases of NICTH involve a tumor in one of these sites.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

> “Given the relative infrequency of testing for IGF‐1, IGF‐2 and pro‐IGF‐2 testing, the diagnosis of NICTH poses considerable challenges and is often overlooked, which may lead to significant clinical consequences.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

Additional sources: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
